Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease -February 27, 2024 at 02:01 pm EST

BETHESDA, Md., Feb. 27, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule...

Related Keywords

Australia ,Nic Johnson ,Matthias Alder ,Elio Ambrosio ,Bellberry Human Research Ethics Committee ,Exchange Commission ,Linkedin ,Gain Therapeutics Inc ,Nasdaq ,Company Annual Report On Form ,Michaelj Fox Foundation For Parkinson Research ,Silverstein Foundation For Parkinson ,Exchange Commission On ,Multiple Ascending Dose ,Single Ascending Dose ,Chief Executive Officer ,Silverstein Foundation ,Gain Therapeutics ,Site Directed Enzyme Enhancement Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,